Avalo Therapeutics’ (AVTX) “Outperform” Rating Reaffirmed at Wedbush

Wedbush restated their outperform rating on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report sent to investors on Thursday morning,RTT News reports. The firm currently has a $18.00 target price on the stock.

Other research analysts have also recently issued research reports about the company. BTIG Research began coverage on Avalo Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price on the stock. Piper Sandler began coverage on shares of Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.33.

Avalo Therapeutics Trading Up 2.9 %

Shares of AVTX opened at $8.22 on Thursday. Avalo Therapeutics has a 52-week low of $4.43 and a 52-week high of $34.46. The business’s fifty day moving average is $7.44 and its 200-day moving average is $9.11.

Hedge Funds Weigh In On Avalo Therapeutics

Several large investors have recently bought and sold shares of AVTX. Ikarian Capital LLC increased its stake in shares of Avalo Therapeutics by 1,673.0% in the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after buying an additional 915,629 shares during the period. RA Capital Management L.P. bought a new stake in Avalo Therapeutics during the 3rd quarter worth approximately $9,186,000. Geode Capital Management LLC grew its holdings in Avalo Therapeutics by 937.0% during the 4th quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock worth $779,000 after acquiring an additional 94,742 shares during the last quarter. Bank of Montreal Can acquired a new position in Avalo Therapeutics in the 4th quarter valued at approximately $446,000. Finally, Walleye Capital LLC bought a new position in shares of Avalo Therapeutics during the fourth quarter valued at $145,000. 87.06% of the stock is currently owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.